Join STEMCELL Technologies' experts as they discuss the use of human intestinal organoid cultures in drug discovery and toxicity testing.

Human intestinal organoids provide a scalable and highly predictive model system for studying the effects of novel therapeutics in vitro. Intestinal organoids contain the relevant cell types that constitute the intestinal epithelium and, as such, can be maintained in various states of proliferation or differentiation. These physiologically relevant models reveal the toxicity of compounds that can not be seen in Caco-2 cells, which are frequently used to model the intestine during drug development programs.

In this webinar, Dr. Victoria Conlin and Danny Leung from STEMCELL Technologies will describe, in detail, what intestinal organoids are, how they mimic the immunocytochemistry and morphology of the human gut epithelium, and how to use organoids for drug screening. They will also discuss the intestinal organoid assays offered by Contract Assay Services at STEMCELL Technologies.

Key Topics Include:

  • Learn about the importance of the intestinal epithelium in early determination of drug toxicity
  • Discover applications of intestinal organoid cultures in:
    • Drug discovery, including how organoid-derived intestinal cell cultures can be applied to assess the toxicity of potential therapeutic compounds
    • Modeling barrier function
  • Explore intestinal organoid assays provided by Contract Assay Services, STEMCELL Technologies’ contract research organization

Presenters

Senior Manager, Contract Assay Services
Business Operations
STEMCELL Technologies

Dr. Victoria Conlin is the Senior Manager of Contract Assay Services at STEMCELL Technologies. She obtained her PhD in Respiratory Physiology at the University of Newcastle upon Tyne, England. She has worked both in academia and industry researching areas of infectious disease and cell biology throughout various epithelial regions of the body.

Scientist, Contract Assay Services
Business Operations
STEMCELL Technologies

Danny Leung is the Lead Scientist in Assay Development for Contract Assay Services at STEMCELL Technologies. Danny has 30 years of experience in the field of assay development for pharmacology and toxicology.

Production Partner

STEMCELL Technologies Inc.

STEMCELL Technologies provides specialized cell culture media, cell isolation products, and reagents for your cell therapy and drug discovery research. Our ethically sourced human primary cell portfolio includes products from peripheral blood, cord blood, and bone marrow.

Additional Content From STEMCELL Technologies Inc.

Additional Content From Scientist.com

Related Content